X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (386) 386
index medicus (338) 338
female (232) 232
male (232) 232
hematology (226) 226
middle aged (222) 222
aged (218) 218
oncology (185) 185
adult (181) 181
aged, 80 and over (139) 139
leukemia, lymphocytic, chronic, b-cell - drug therapy (129) 129
abridged index medicus (113) 113
treatment outcome (113) 113
article (109) 109
rituximab (97) 97
leukemia (95) 95
cancer (91) 91
hemic and lymphatic diseases (89) 89
prognosis (86) 86
chronic lymphocytic leukemia (83) 83
survival (75) 75
antineoplastic combined chemotherapy protocols - therapeutic use (73) 73
cll (71) 71
therapy (71) 71
leukemia, lymphocytic, chronic, b-cell - genetics (70) 70
leukemia, lymphocytic, chronic, b-cell - pathology (70) 70
antineoplastic agents - therapeutic use (64) 64
care and treatment (63) 63
disease-free survival (60) 60
fludarabine (59) 59
chronic lymphocytic-leukemia (53) 53
expression (52) 52
research (52) 52
hematology, oncology and palliative medicine (50) 50
cyclophosphamide (49) 49
adolescent (47) 47
leukemia, lymphocytic, chronic, b-cell - mortality (47) 47
animals (46) 46
apoptosis (45) 45
chemotherapy (44) 44
initial therapy (44) 44
patients (43) 43
leukemia, lymphocytic, chronic, b-cell - therapy (42) 42
vidarabine - analogs & derivatives (42) 42
chronic lymphatic leukemia (41) 41
ibrutinib (41) 41
immune system diseases (41) 41
retrospective studies (41) 41
lymphoma (40) 40
recurrence (39) 39
dose-response relationship, drug (38) 38
analysis (37) 37
follow-up studies (37) 37
lymphoid neoplasia (37) 37
risk factors (36) 36
survival rate (36) 36
disease progression (35) 35
leukemia, lymphocytic, chronic, b-cell - metabolism (35) 35
antineoplastic combined chemotherapy protocols - adverse effects (34) 34
remission induction (34) 34
young adult (34) 34
mutation (33) 33
antibodies, monoclonal - therapeutic use (32) 32
kaplan-meier estimate (32) 32
pyrimidines - therapeutic use (32) 32
drug administration schedule (31) 31
lymphomas (31) 31
survival analysis (31) 31
acute myeloid-leukemia (30) 30
alemtuzumab (30) 30
chemoimmunotherapy (30) 30
cyclophosphamide - administration & dosage (30) 30
diagnosis (30) 30
drug therapy (30) 30
antibodies, monoclonal - administration & dosage (29) 29
cells (29) 29
clinical trials (29) 29
antineoplastic agents - administration & dosage (28) 28
antineoplastic combined chemotherapy protocols - administration & dosage (28) 28
mice (28) 28
patient outcomes (28) 28
flow cytometry (27) 27
lymphatic leukemia (27) 27
transplantation (27) 27
vidarabine - administration & dosage (27) 27
antineoplastic agents - adverse effects (26) 26
clinical trials and observations (26) 26
immunology (26) 26
leukemia, lymphocytic, chronic, b-cell - diagnosis (26) 26
leukemia, lymphocytic, chronic, b-cell - immunology (26) 26
antineoplastic agents - pharmacology (25) 25
apoptosis - drug effects (25) 25
open-label (25) 25
pyrimidines - administration & dosage (25) 25
tyrosine (25) 25
inhibitor (24) 24
tumor cells, cultured (24) 24
acute myelogenous leukemia (23) 23
chronic myelogenous leukemia (23) 23
combination (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 7, pp. 1576 - 1583
Journal Article
Leukemia, ISSN 0887-6924, 09/2017, Volume 31, Issue 9, pp. 1872 - 1881
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 04/2018, Volume 32, Issue 4, pp. 920 - 930
Acalabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously... 
APOPTOSIS | BRUTONS TYROSINE KINASE | ONCOLOGY | IN-VIVO | BONE-MARROW | INITIAL THERAPY | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | OPEN-LABEL | INHIBITOR | HEMATOLOGY | EXPRESSION | Protein-Tyrosine Kinases - metabolism | Humans | Pyrazines - administration & dosage | Benzamides - administration & dosage | Chemokine CCL3 - metabolism | Chemokine CCL4 - metabolism | B-Lymphocytes - metabolism | Pyrimidines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | B-Lymphocytes - drug effects | Cell Movement - drug effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Adoptive Transfer - methods | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Proteomics | Combined Modality Therapy - methods | Mice | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Clinical Trials, Phase I as Topic | Sulfonamides - administration & dosage | Clinical Trials, Phase II as Topic | Drug Resistance, Neoplasm - drug effects | Chronic lymphocytic leukemia | Pharmacology, Experimental | Oncology, Experimental | Development and progression | Pharmacology | Research | Drug therapy, Combination | Drug therapy | Cancer | Therapy | Leukocyte migration | Leukemia | Carbon tetrachloride | Clinical trials | Immunoblotting | B-cell receptor | Kinases | Adoptive transfer | Cell adhesion & migration | Proteins | Signal transduction | Lymphocytes | Peripheral blood | Remission | Protein-tyrosine kinase | Tyrosine | Medical research | Pharmacodynamics | Chronic lymphatic leukemia | Cell survival | CCL3 protein | Lymphatic leukemia | CCL4 protein | Patients | Bruton's tyrosine kinase | Signaling | Protein arrays | Lymphocytes B | Chemokines | Combinatorial analysis | Cell migration | chronic lymphocytic leukemia | Acalabrutinib | venetoclax | BTK inhibitor
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 31, pp. 3722 - 3723
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 12/2017, Volume 15, Issue 12, pp. 1692 - 1703
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Agammaglobulinaemia Tyrosine Kinase | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage
Journal Article